With Vandetanib (Zactima™) In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented At American Society Of Clinical Oncology

Data from the Phase III ZODIAC1 study in advanced non-small cell lung cancer patients, with the investigational drug vandetanib, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Orlando. Continue reading ...